NASDAQ:INM
Inmed Pharmaceuticals Inc. Stock News
$0.254
+0.0160 (+6.72%)
At Close: Jun 21, 2024
InMed to Present at the Emerging Growth Conference
05:18pm, Monday, 10'th Jun 2024
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a clinical stage pharmaceutical company focused on developing a pip
InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
08:30am, Tuesday, 14'th May 2024
Reported positive preclinical data in both its Alzheimer's and dry AMD programs Closed Fiscal Q3 with cash position of US$7.9 million Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - InM
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board
08:00am, Thursday, 18'th Apr 2024
Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the research, development, manufacturing, and commerci
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
08:00am, Tuesday, 16'th Apr 2024
Small molecule drug acting as a preferential signaling ligand for CB1/CB2 Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical d
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies
08:00am, Thursday, 04'th Apr 2024
INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling pathway In Vivo studies demonstrate INM-901 reduces neuroinflammation and improves n
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
08:30am, Wednesday, 20'th Mar 2024
Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization o
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
05:41pm, Tuesday, 13'th Feb 2024
Advancing two new preclinical programs in Alzheimer's and Age-Related Macular Degeneration Closed calendar year 2023 with cash position of US$9.5 million 164% revenue growth in the commercial BayMedic
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
08:00am, Friday, 09'th Feb 2024
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
08:00am, Tuesday, 16'th Jan 2024
Advancing INM-901 as a multimodal treatment option for Alzheimer's Disease Advancing INM-089 in the treatment of Age-related Macular Degeneration Actively seeking partnerships to advance INM-755 in De
InMed Announces Results of 2023 Annual General Meeting
06:03pm, Tuesday, 19'th Dec 2023
Vancouver, British Columbia--(Newsfile Corp. - December 19, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufa
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update
08:04am, Tuesday, 14'th Nov 2023
Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufact
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023
08:00am, Thursday, 02'nd Nov 2023
Vancouver, British Columbia--(Newsfile Corp. - November 2, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufactur
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufactur
Why Is InMed Pharmaceuticals (INM) Stock Down 25% Today?
09:00am, Wednesday, 25'th Oct 2023
InMed Pharmaceuticals (NASDAQ: INM ) stock is falling on Wednesday after the pharmaceutical company's shares underwent a massive rally on Tuesday! INM stock was up 70.5% when normal trading hours end
